DENVER—Utah’s attorney general sued GlaxoSmithKline Nov. 9, alleging the drug company defrauded the state’s Medicaid program and illegally misled consumers in the state by marketing Avandia as a “wonder drug” for the treatment of type 2 diabetes (Shurtleff v. GlaxoSmithKline).
The complaint in state court alleges GSK defrauded Utah out of $7.8 million, the amount the state’s Medicaid program spent on Avandia (rosiglitazone maleate) from Jan. 1, 2001, to June 30, 2010, according to Utah Attorney General Mark Shurtleff (R).
Avandia was identified in various studies, including one in the New England Journal of Medicine, as significantly ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.